The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
The multiple roles of microRNA-155 in oncogenesis
Open accessAbstract
The microRNA miR-155 is prominent in cancer biology. Among microRNAs that have been linked to cancer, it is the most commonly overexpressed in malignancies (PNAS 109:20047-20052, 2012). Since its discovery, miR-155 has been implicated in promoting cancers of the breast, lung, liver, and lymphatic system. As such, targeted therapies may prove beneficial to cancer treatment. This review discusses the important role of miR-155 in oncogenesis. It synthesizes information from ten recent papers on miR-155, and includes an analysis and discussion of its association with cancer, interactions with other miRNAs, mechanisms of action, and the most promising available treatment options.Current debates in the field include the importance of miRNAs in general and their utility as targets in preventing tumorigenesis (Blood 119:513-520, 2012). Most of the papers being reviewed here confirm the role of miR-155 in oncogenesis (EMBO Mol Med 1:288-295, 2009). While there is some controversy surrounding recent research that claims that miR-155 may display anti-oncogenic or pro-immunological benefits (Cell Rep 2:1697-1709, 2012), most research seems to point to the importance of anti-miRs, with anti-miR-155 in particular, for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Normal BRCA1 represses miR-155 expression via its association with HDAC2 [[20]].](/paper-figures/5c68990cef9543a4912550d29027a6c9/the-multiple-roles-of-microrna-155-in-oncogenesis-figure-1.jpg)
![Figure 2 The interplay of MiR-155 in inflammation and the Warburg effect of cancer [[16]].](/paper-figures/a910389778a04a9d8b1eaaa19e43de71/the-multiple-roles-of-microrna-155-in-oncogenesis-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
MicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
(2008) · doi:10.1038/nrg2290 · Cited by 5,199
Regulation of the Germinal Center Response by MicroRNA-155
Thai, T., Calado, D. P., Casola, S. S., Ansel, K. M., Xiao, C., Xue, Y., Murphy, A. J., Frendewey, D. A., Valenzuela, D. M., Kutok, J. L., et al. (2007) · Science · doi:10.1126/science.1141229 · Cited by 1,477
Inflammation and cancer: An ancient link with novel potentials
Hussain, S. P., & Harris, C. C. (2007) · International Journal of Cancer · doi:10.1002/ijc.23173 · Cited by 1,113
miR-155 gene: A typical multifunctional microRNA
Faraoni, I., Antonetti, F. R., Cardone, J., & Bonmassar, E. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.02.013 · Cited by 815
Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways
Schetter, A. J., Heegaard, N. H. H., & Harris, C. C. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp272 · Cited by 671
Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma
Babar, I., Cheng, C. J., Booth, C. J., Liang, X., Weidhaas, J. B., Saltzman, W. M., & Slack, F. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201516109 · Cited by 506
Epigenetic diet: impact on the epigenome and cancer
Hardy, T. M., & Tollefsbol, T. O. (2011) · Epigenomics · doi:10.2217/epi.11.71 · Cited by 416
Jiang, S., Zhang, L.-F., Zhang, H.-W., Hu, S. N., Lu, M.-H., Liang, S., Li, B., Li, Y., Li, D., Wang, E.-D., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.45 · Cited by 358
Cited by
Sorted by citations
Items 101–136 of 136
Lao, T. D., & Le, T. A. H. (2019) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2019.0089 · Cited by 9
“As such, miR-155 has been considered an important target for diagnosis, prognosis, and cancer therapy (Higgs and Slack, 2013).”
Micro-RNAs in breast cancer progression and metastasis: A chromatin and metabolic perspective
Sikder, S., Bhattacharya, A., Agrawal, A., Sethi, G., & Kundu, T. K. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38193 · Cited by 9
“The pro-inflammatory cytokines released by them further induce the expression of miR-155 in breast cancer cells [114].”
BackgroundCancer Risk in Patients With Congenital Heart Disease Exposed to Radiation From Cardiac Procedures
Borghini, A., Campolo, J., Annoni, G., Giuli, V., Sicari, R., Peretti, A., Mercuri, A., Picano, E., & Andreassi, M. G. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.12.028 · Cited by 8
The Role of miRNAs in Diagnosis, Prognosis and Treatment Prediction in Cervical Cancer
Bălăcescu, O., Bălăcescu, L., Baldasici, O., Tudoran, O. M., & Achimaș-Cădariu, P. (2017) · InTech eBooks · doi:10.5772/68011 · Cited by 8
Mironova, N. L., & Vlassov, V. V. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01019 · Cited by 8
“However, although there is a lot of evidence for the oncogenic role of miRNA-155, it can also act as a tumour suppressor (Higgs and Slack, 2013).”
BackgroundChen, G., Wang, S., Wang, F., Yang, C., Zhang, R., Liu, P., Ning, J., Wang, S., Ma, F., Xu, L., et al. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102492 · Cited by 6
Espina-Ordoñez, M., Balderas-Martínez, Y. I., Torres‐Machorro, A. L., Herrera, I., Maldonado, M., Romero, Y., Toscano-Marquez, F., Pardo, A., Selman, M., & Cisneros, J. (2024) · Non-coding RNA Research · doi:10.1016/j.ncrna.2024.02.010 · Cited by 5
“MiR-155-5p is overexpressed in cancer and is essential to sustain cell proliferation [13].”
BackgroundKlimenko, O. V., & Sidorov, A. (2019) · Non-coding RNA Research · doi:10.1016/j.ncrna.2019.03.001 · Cited by 5
Kharboush, T. G., Ahmed, I. A. E., Farag, A. A., Kharboush, T. G., Sayed, A. E. H., Abdel-Kareim, A. M., Mohaini, M. A., Attia, H., Eid, R. A., Zaki, M. S. A., et al. (2023) · Environmental Science and Pollution Research · doi:10.1007/s11356-023-31283-0 · Cited by 4
“…and decreased gradually over time. miRr-155 is predominantly known for its oncogenic roles in lung cancer and several researches established a link between the overexpression of miR-155 and lung cancer diagnosis, prognosis and pathogenesis (Higgs and Slack 2013, Hou et al. 2016; Shao et al. 2019).”
BackgroundUpregulation of miRNA-155 in Nasopharyngeal Carcinoma Pa-tients
Lao, T. D., Nguyen, M. T., Nguyen, D. H., & Le, T. A. H. (2021) · Iranian Journal of Public Health · doi:10.18502/ijph.v50i8.6810 · Cited by 4
“Up to date, there are many researches of abnormal regulation of miR-155 associated the pathogenesis of various human tumors, including NPC (5, 6, 12-15).”
BackgroundROLE OF MICRORNA-155 AS A DIAGNOSTIC BIOMARKER FOR HUMAN PAPILLOMAVIRUS ASSOCIATED CERVICAL CANCER
Jihad, N. A., & Issa, Y. W. (2021) · Wiadomości Lekarskie · doi:10.36740/wlek202109210 · Cited by 4
Anari, S. R. M., Kheirkhah, B., Amini, K., & Roozafzai, F. (2023) · PubMed Central · doi:10.30476/ijms.2022.91669.2282 · Cited by 4
Extracellular vesicles show promise for cancer theranostics
Segal, M., & Slack, F. J. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.03.19 · Cited by 4
“Upregulated miRNAs in cancer cells promote carcinogenesis by attenuating tumor suppressor genes, and are known as oncomiRs (oncogenic miRNAs) (15).”
BackgroundPharmacological interventions targeting β-adrenoceptors in colorectal cancer: an evolving paradigm
Ghosn, A., Bassam, K., Zein, M. A., Nasser, S. A., Pintus, G., & Eid, A. H. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01925-5 · Cited by 3
“…that has been extensively implicated in colorectal cancer (CRC) pathogenesis (Gao et al. 2018; Hu et al. 2014; Liu et al. 2014; Ling et al. 2013; Higgs and Slack 2013). miR-155 exerts profound effects on proliferation, invasion, chemoresistance, and immune evasion in CRC, making it a critical…”
Non-coding RNA therapy in cancer
Součková, K., Ivković, T. C., & Slabý, O. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819178-1.00020-4 · Cited by 3
Cross talk between genetics and biochemistry in the pathogenesis of hepatocellular carcinoma
Üçdal, M. T., Burus, A., & Celtikci, B. (2024) · Hepatology forum/Hepatology forum (Online) · doi:10.14744/hf.2023.2023.0028 · Cited by 2
“…[48] miR-101 FOS oncogene [49] miR-106b EMT [50] miR-130b PPAR-γ , TP53INP1 [51] miR-155 c-Myc, C/EBP β , APC, β -catenin, Cyclin D1, TP53INP1 [52] miR-197 Wnt/ β -catenin, Axin-2, NKD1 and DKK2 [53] miR-219-5p Cadherin 1 [54] miR-221 and miR-222 PHF2, AKT pathway, PTEN, CDK inhibitor p27 and…”
The role of miRNAs as biomarkers in cancer
Ou, Y., & Ren, Z. (2024) · Asia-Pacific Journal of Oncology · doi:10.32948/ajo.2024.10.18 · Cited by 2
Combined replacement of lnc-MEG3 and miR-155 elicit tumor suppression in multiple myeloma
El-Khazragy, N. N., Abdelrahman, S. E., Darwish, A., & Hemida, E. H. A. (2025) · Epigenomics · doi:10.1080/17501911.2025.2453413 · Cited by 2
HTLV-1 infection and microRNAs: unraveling the complex crosstalk
Edalat, F., Letafati, A., Kaghazchi, T., Sadeghi, M., Taheri, A., Shikki, A., Garkani, S. H., Afrozi, M., Norouzi, M., & Mozhgani, S. (2025) · Infectious Agents and Cancer · doi:10.1186/s13027-025-00658-y · Cited by 1
MicroRNA-Mediated Metabolic Control in HCC: From Molecular Networks to Therapy.
Alrawi, D., Farhan, S. R., Alkhathami, A. G., Hsu, C.-Y., Al-Khafaji, Z., El-Sehrawy, A. A. M. A., Mustafa, Y. F., Nabil, W., & Al-Mashhadani, Z. (2025) · Experimental Cell Research · doi:10.1016/j.yexcr.2025.114853 · Cited by 3
Do, E., Puro, D., & Hansda, S. (2026) · Biology · doi:10.3390/biology15141106 · Cited by 1
Micro-RNA 155 in non-Hodgkin lymphoma
Hamed, H. B., Elgammal, S. A., Narouz, M. W., & Elnaggar, M. (2021) · The Egyptian Journal of Haematology · doi:10.4103/ejh.ejh_4_20 · Cited by 1
Expression of MicroRNA-155 in Hepatitis B Virus-Related to Hepatocellular Carcinoma
Renovaldi, D., Radityaningsih, J., Lestari, P., Qoriansas, N., Heriyanto, D. S., Ratnasari, N., & Haryana, S. M. (2021) · Advances in health sciences research/Advances in Health Sciences Research · doi:10.2991/ahsr.k.210115.003 · Cited by 1
“MicroRNA-155 has been widely reported to have associations with the progression of leukemia, breast cancer, lung cancer, and stomach tumors and is often a target in diagnosis, prognosis, and therapy [8,9].”
BackgroundDelivery strategies of RNA therapeutics for ex vivo and in vivo B-cell malignancies
Stotsky‐Oterin, L., Tarab‐Ravski, D., & Peer, D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85781-9.00005-1 · Cited by 1
Interplay Between Metabolism and Oncogenic Process: Role of microRNAs
Ambedkar, B. R. (2015)
REGULATING MIRNA BIOGENESIS BY SMALL MOLECULES
Yan, H. (2018) · UNM’s Digital Repository (University of New Mexico)
Nardinelli, L. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2020.tde-22092021-115923
Ghafary, Z., Salimi, A., Hallaj, R., & Ghasemi, F. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4052314
(2022) · Al-Azhar University Journal of Virus Researches and Studies · doi:10.21608/aujv.2022.278217
Dhuri, K., Gaddam, R. R., Vikram, A., Slack, F. J., & Bahal, R. (2023) · doi:10.1158/0008-5472.c.6513501.v1
Communication in miRNAs Between Inflammation and Cancer
Fujii, Y. R. (2023) · Springer eBooks · doi:10.1007/978-981-99-3165-1_7
Soy\'s secret weapon: Genistein\'s fight against triple-negative breast cancer
Kma, L., Marak, M., & Marwein, R. (2024) · IP International Journal of Comprehensive and Advanced Pharmacology · doi:10.18231/j.ijcaap.2024.036
“51,52 Treatment with GEN has shown to decrease miR-155 expression in TNBC cells.”
From Exposure to Effect: Genetic and Epigenetic Biomarker-Guided Risk Assessment in Cardiac Imaging
Borghini, A., Gorini, F., Palazzo, M., & Daher, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073041
“Notably, it is overexpressed in cells from patients with acute myeloid leukemia and in several solid tumors arising in highly radiosensitive organs, such as the lung, breast, and colon [87].”
Viknesh, K., Manoharan, J., Cho, W. C., Alothaim, A. S., Vijayakumar, R., Vijayalakshmi, P., Yogeswari, C., Ramanathan, S., Likson, A., Desai, D., et al. (2026) · Chemical Papers · doi:10.1007/s11696-026-05399-9
Radiolabelled Antisense miRNA Oligonucleotides for Molecular Imaging and Therapeutic Applications
Bonanno, C., & Romeo, G. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18101197
“In all these types of tumours, overexpression of this miRNA has been highlighted [62].”
Hu, D., Yang, Y., Du, S., Yang, F., Zhang, Y., Gong, M., Yang, X., Chen, R., Zeng, Q., & Xu, Y. (2026) · Toxicology Research · doi:10.1093/toxres/tfag081
Metadata
- Authors
- Higgs, G., & Slack, F.
- Affiliations
- Yale University (US)
- Corresponding author
- Higgs, Gadareth
- ORCID
- Slack, Frank
- Venue
- Journal of Clinical Bioinformatics
- Publisher
- ClinTransMed, AB
- Published
- 2013
- Volume
- 3
- Issue
- 1
- Pages
- 17
- ISSN
- 2043-9113 (ISSN-L)
- PMC
- PMC3849775
- OpenAlex
- W2128733367
- Cited by
- 137
- References
- 33
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 7 · 2023: 11 · 2022: 10 · 2021: 12 · 2020: 10 · 2019: 16 · 2018: 12 · 2017: 9 · 2016: 10 · 2015: 17 · 2014: 12
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Journal of Clinical Bioinformatics (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Yale University
- Yale Cancer Center
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- miR-155, microRNA, carcinogenesis, cancer, anti-miR therapy, microRNA interactions, breast cancer, lung cancer, liver cancer, lymphoma, tumor immunology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
